WCLC 2025: Combination therapy achieves durable response in advanced lung cancer patients
MD Anderson Research Highlight September 08, 2025
KRAS G12C mutations are among the most common drivers of non-small cell lung cancer (NSCLC), yet first-line targeted therapy options remain limited. Olomorasib, a selective KRAS G12C inhibitor, has shown promising results in combination with chemoimmunotherapy. In an integrated analysis from the Phase I LOXO-RAS-20001 and Phase III SUNRAY-01 trials, , and colleagues examined the safety and preliminary efficacy of olomorasib (50 or 100 mg twice daily) with chemoimmunotherapy in 77 patients with advanced KRAS G12C-mutant NSCLC. The overall response rate was 61% and the disease control rate was 90% with the combination. Responses occurred early across all PD-L1 expression levels, and the regimen demonstrated a manageable safety profile. Based on these results, the 100 mg (twice daily) dose of olomorasib is being evaluated in the ongoing Phase III SUNRAY-01 trial. These findings support olomorasib as a potential first-line treatment for patients with KRAS G12C-mutant NSCLC. Negrao presented the data at the World Conference of Lung Cancer (WCLC) .
This combination demonstrates meaningful clinical activity in the first-line treatment of KRAS G12C-mutant NSCLC, including in patients with low or absent PD-L1 expression¡ªa subgroup that typically has limited benefit from immunotherapy alone. These results suggest olomorasib plus chemoimmunotherapy could address an unmet need for these patients.